Lyra Therapeutics, Inc.
LYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -86.3% | 0% | -12.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -300% | -9.3% | 100% | 100% |
| R&D Expenses | $4 | $5 | $5 | $6 |
| G&A Expenses | $0 | $4 | $3 | $4 |
| SG&A Expenses | $2 | $4 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $1 | $2 |
| Operating Expenses | $6 | $8 | $9 | $12 |
| Operating Income | -$6 | -$8 | -$9 | -$11 |
| % Margin | -25,032% | -4,605.5% | -4,831.1% | -5,458.4% |
| Other Income/Exp. Net | $0 | $1 | $0 | $0 |
| Pre-Tax Income | -$6 | -$7 | -$9 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$7 | -$9 | -$11 |
| % Margin | -23,936% | -4,063.9% | -4,670.5% | -5,253.1% |
| EPS | -3.38 | -5.51 | -0.13 | -0.17 |
| % Growth | 38.7% | -4,138.5% | 23.5% | – |
| EPS Diluted | -3.38 | -5.51 | -0.13 | -0.17 |
| Weighted Avg Shares Out | 2 | 1 | 66 | 65 |
| Weighted Avg Shares Out Dil | 2 | 1 | 66 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$7 | -$8 | -$10 |
| % Margin | -23,524% | -3,953.6% | -4,277.6% | -4,600.5% |